The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.

Anastasilakis, Athanasios D; Makras, Polyzois; Polyzos, Stergios A; Papapoulos, Socrates E

Anastasilakis, Athanasios D; Makras, Polyzois; Polyzos, Stergios A; Papapoulos, Socrates E.

Afiliação

Anastasilakis AD; Department of Endocrinology, 424 Military General Hospital, Ring Road, 564 29 N. Efkarpia, Thessaloniki, Greece. a.anastasilakis@gmail.com.
Makras P; Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
Polyzos SA; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
Papapoulos SE; First Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Calcif Tissue Int ; 113(4): 469-473, 2023 10.

Article em En | MEDLINE | ID: mdl-37535102

Assuntos

Conservadores da Densidade Óssea; Osteoporose Pós-Menopausa; Humanos; Feminino; Osteoporose Pós-Menopausa/tratamento farmacológico; Ácido Zoledrônico/uso terapêutico; Denosumab; Densidade Óssea; Estudos Prospectivos

Palavras-chave

Bone mineral density; Denosumab discontinuation; Oteoporosis; Rebound; Zoledronate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose Pós-Menopausa / Conservadores da Densidade Óssea Tipo de estudo: Clinical_trials / Observational_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google